Search
01/04/2022
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome
Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).
01/04/2022
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Blauvelt, A, Tsai, TF, Langley, RG, Miller, M, Shen, YK, You, Y, Yang, YW, Papp, KA, Puig, L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4)DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13.800(Q1/1D).
01/04/2022
RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy
Fernandez-Simon, E, Suarez-Calvet, X, Carrasco-Rozas, A, Pinol-Jurado, P, Lopez-Fernandez, S, Pons, G, Serra, JJB, de la Torre, C, De Luna, N, Gallardo, E, Diaz-Manera, J. RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy. Journal of Cachexia Sarcopenia and Muscle. 2022; 13(2)DOI:10.1002/jcsm.12923. PMID:35132805. IF:8.900(Q1/1D).
01/04/2022
Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy
Subiela, JD, Faba, OR, Aumatell, J, Calderon, J, Mercade, A, Balana, J, Esquinas, C, Algaba, F, Breda, A, Palou, J. Contemporary outcomes of bladder carcinoma in situ treated with an adequate bacille Calmette-Guerin immunotherapy. BJU INTERNATIONAL. 2022; 129(4)DOI:10.1111/bju.15567. PMID:34375494. IF:4.500(Q1/3D).
01/04/2022
Can cystinuria decrease the effectiveness of RIRS with high-power ho:yag laser in children? Outcomes from a tertiary endourology referral center
Madarriaga, YQ, Gallardo, AB, de Knecht, EL, Lang, GM, Redorta, JP, Tur, AB. Can cystinuria decrease the effectiveness of RIRS with high-power ho:yag laser in children? Outcomes from a tertiary endourology referral center. Urolithiasis. 2022; 50(2)DOI:10.1007/s00240-022-01301-w. PMID:35084538. IF:3.100(Q2/4D).
01/04/2022
Guidelines for living donor kidney transplantation
Frutos, MA, Crespo, M, Valentin, MD, Alonso-Melgar, A, Alonso, J, Fernandez, C, Garcia-Erauzkin, G, Gonzalez, E, Gonzalez-Rinne, AM, Guirado, L, Gutierrez-Dalmau, A, Huguet, J, del Moral, JLL, Musquera, M, Paredes, D, Redondo, D, Revuelta, I, Hofstadt, CJVD, Alcaraz, A, Alonso-Hernandez, A, Alonso, M, Bernabeu, P, Bernal, G, Breda, A, Cabello, M, Caro-Oleas, JL, Cid, J, Diekmann, F, Espinosa, L, Facundo, C, Garcia, M, Gil-Vernet, S, Lozano, M, Mahillo, B, Martinez, MJ, Miranda, B, Oppenheimer, F, Palou, E, Perez-Saez, MJ, Peri, L, Rodriguez, O, Santiago, C, Tabernero, G, Hernandez, D, Dominguez-Gil, B, Pascual, J. Guidelines for living donor kidney transplantation. NEFROLOGIA. 2022; 42DOI:10.1016/j.nefro.2021.10.002. PMID:36443207. IF:2.600(Q3/6D).